Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  6/30/2016
Lifespan: The Miriam Hospital
mi
from
Providence, RI
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 6/30/2016
Lifespan: The Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  6/30/2016
Veterans Affairs Medical Center - Dallas
mi
from
Dallas, TX
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 6/30/2016
Veterans Affairs Medical Center - Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  6/30/2016
Simmons Cancer Center at University of Texas Southwestern Medical Center - Dalas
mi
from
Dallas, TX
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 6/30/2016
Simmons Cancer Center at University of Texas Southwestern Medical Center - Dalas
mi
from
Dallas, TX
Click here to add this to my saved trials
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  6/30/2016
Green Mountain Oncology Group
mi
from
Bennington, VT
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 6/30/2016
Green Mountain Oncology Group
mi
from
Bennington, VT
Click here to add this to my saved trials
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  6/30/2016
Vermont Cancer Center at University of Vermont
mi
from
Burlington, VT
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 6/30/2016
Vermont Cancer Center at University of Vermont
mi
from
Burlington, VT
Click here to add this to my saved trials
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  6/30/2016
Veterans Affairs Medical Center - White River Junction
mi
from
White River Junction, VT
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 6/30/2016
Veterans Affairs Medical Center - White River Junction
mi
from
White River Junction, VT
Click here to add this to my saved trials
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  6/30/2016
Martha Jefferson Hospital
mi
from
Charlottesville, VA
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 6/30/2016
Martha Jefferson Hospital
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  6/30/2016
Virginia Oncology Associates - Norfolk
mi
from
Norfolk, VA
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 6/30/2016
Virginia Oncology Associates - Norfolk
mi
from
Norfolk, VA
Click here to add this to my saved trials
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  6/30/2016
MBCCOP - Massey Cancer Center
mi
from
Richmond, VA
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 6/30/2016
MBCCOP - Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  6/30/2016
Oncology and Hematology Associates of Southwest Virginia
mi
from
Roanoke, VA
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 6/30/2016
Oncology and Hematology Associates of Southwest Virginia
mi
from
Roanoke, VA
Click here to add this to my saved trials
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  6/30/2016
St Mary's Medical Center
mi
from
Huntington, WV
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 6/30/2016
St Mary's Medical Center
mi
from
Huntington, WV
Click here to add this to my saved trials
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  6/30/2016
Ministry Medical Group - Northern Region
mi
from
Rhinelander, WI
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 6/30/2016
Ministry Medical Group - Northern Region
mi
from
Rhinelander, WI
Click here to add this to my saved trials
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  6/30/2016
McGill University
mi
from
Montreal,
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 6/30/2016
McGill University
mi
from
Montreal,
Click here to add this to my saved trials
Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer
Phase I/II Double Blinded Randomized Study to Determine the Tolerability and Efficacy of 2 Different Doses of Revlimid (CC-5013, Lenalidomide) in Biochemically Relapsed Prostate Cancer Patients (M0) After Local Treatment
Status: Enrolling
Updated:  6/30/2016
The Harry and Jeanette Weinberg Building
mi
from
Baltimore, MD
Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer
Phase I/II Double Blinded Randomized Study to Determine the Tolerability and Efficacy of 2 Different Doses of Revlimid (CC-5013, Lenalidomide) in Biochemically Relapsed Prostate Cancer Patients (M0) After Local Treatment
Status: Enrolling
Updated: 6/30/2016
The Harry and Jeanette Weinberg Building
mi
from
Baltimore, MD
Click here to add this to my saved trials
Vigorous or Moderate Exercise in Enhancing Active Surveillance in Patients With Localized Prostate Cancer
Enhancing Active Surveillance With Exercise (EASE): A Pilot Randomized Trial in Localized Prostate Cancer Survivors
Status: Enrolling
Updated:  7/11/2016
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Vigorous or Moderate Exercise in Enhancing Active Surveillance in Patients With Localized Prostate Cancer
Enhancing Active Surveillance With Exercise (EASE): A Pilot Randomized Trial in Localized Prostate Cancer Survivors
Status: Enrolling
Updated: 7/11/2016
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Vigorous or Moderate Exercise in Enhancing Active Surveillance in Patients With Localized Prostate Cancer
Enhancing Active Surveillance With Exercise (EASE): A Pilot Randomized Trial in Localized Prostate Cancer Survivors
Status: Enrolling
Updated:  7/11/2016
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Vigorous or Moderate Exercise in Enhancing Active Surveillance in Patients With Localized Prostate Cancer
Enhancing Active Surveillance With Exercise (EASE): A Pilot Randomized Trial in Localized Prostate Cancer Survivors
Status: Enrolling
Updated: 7/11/2016
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/12/2016
CCOP - Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/12/2016
CCOP - Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/12/2016
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/12/2016
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Click here to add this to my saved trials
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/12/2016
CCOP - Cedar Rapids Oncology Project
mi
from
Cedar Rapids, IA
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/12/2016
CCOP - Cedar Rapids Oncology Project
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/12/2016
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/12/2016
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Click here to add this to my saved trials
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/12/2016
Siouxland Hematology-Oncology
mi
from
Sioux City, IA
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/12/2016
Siouxland Hematology-Oncology
mi
from
Sioux City, IA
Click here to add this to my saved trials
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/12/2016
CCOP - Wichita
mi
from
Wichita, KA
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/12/2016
CCOP - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/12/2016
CCOP - Ochsner
mi
from
New Orleans, LA
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/12/2016
CCOP - Ochsner
mi
from
New Orleans, LA
Click here to add this to my saved trials
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/12/2016
CCOP - Ann Arbor Regional
mi
from
Ann Arbor, MI
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/12/2016
CCOP - Ann Arbor Regional
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/12/2016
CCOP - Duluth
mi
from
Duluth, MN
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/12/2016
CCOP - Duluth
mi
from
Duluth, MN
Click here to add this to my saved trials
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/12/2016
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/12/2016
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/12/2016
CentraCare Clinic
mi
from
Saint Cloud, MN
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/12/2016
CentraCare Clinic
mi
from
Saint Cloud, MN
Click here to add this to my saved trials
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/12/2016
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/12/2016
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Click here to add this to my saved trials
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/12/2016
Medcenter One Health System
mi
from
Bismarck, ND
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/12/2016
Medcenter One Health System
mi
from
Bismarck, ND
Click here to add this to my saved trials
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/12/2016
CCOP - Merit Care Hospital
mi
from
Fargo, ND
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/12/2016
CCOP - Merit Care Hospital
mi
from
Fargo, ND
Click here to add this to my saved trials
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/12/2016
Altru Health Systems
mi
from
Grand Forks, ND
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/12/2016
Altru Health Systems
mi
from
Grand Forks, ND
Click here to add this to my saved trials
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/12/2016
CCOP - Toledo Community Hospital Oncology Program
mi
from
Toledo, OH
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/12/2016
CCOP - Toledo Community Hospital Oncology Program
mi
from
Toledo, OH
Click here to add this to my saved trials
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/12/2016
CCOP - Geisinger Clinic and Medical Center
mi
from
Danville, PA
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/12/2016
CCOP - Geisinger Clinic and Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/12/2016
Rapid City Regional Hospital
mi
from
Rapid City, SD
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/12/2016
Rapid City Regional Hospital
mi
from
Rapid City, SD
Click here to add this to my saved trials
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/12/2016
CCOP - Sioux Community Cancer Consortium
mi
from
Sioux Falls, SD
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/12/2016
CCOP - Sioux Community Cancer Consortium
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/12/2016
Allan Blair Cancer Centre
mi
from
Regina,
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/12/2016
Allan Blair Cancer Centre
mi
from
Regina,
Click here to add this to my saved trials
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  7/12/2016
Veterans Affairs Medical Center - Birmingham
mi
from
Birmingham, AL
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 7/12/2016
Veterans Affairs Medical Center - Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  7/12/2016
University of California San Diego Cancer Center
mi
from
La Jolla, CA
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 7/12/2016
University of California San Diego Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  7/12/2016
UCSF Cancer Center and Cancer Research Institute
mi
from
San Francisco, CA
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 7/12/2016
UCSF Cancer Center and Cancer Research Institute
mi
from
San Francisco, CA
Click here to add this to my saved trials
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  7/12/2016
Veterans Affairs Medical Center - San Francisco
mi
from
San Francisco, CA
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 7/12/2016
Veterans Affairs Medical Center - San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  7/12/2016
CCOP - Christiana Care Health Services
mi
from
Wilmington, DE
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 7/12/2016
CCOP - Christiana Care Health Services
mi
from
Wilmington, DE
Click here to add this to my saved trials
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  7/12/2016
Lombardi Cancer Center-Georgetown University
mi
from
Washington,
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 7/12/2016
Lombardi Cancer Center-Georgetown University
mi
from
Washington,
Click here to add this to my saved trials
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  7/12/2016
Walter Reed Army Medical Center
mi
from
Washington,
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 7/12/2016
Walter Reed Army Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  7/12/2016
Mount Sinai Medical Center CCOP
mi
from
Miami Beach, FL
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 7/12/2016
Mount Sinai Medical Center CCOP
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  7/12/2016
University of Illinois at Chicago Health Sciences Center
mi
from
Chicago, IL
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 7/12/2016
University of Illinois at Chicago Health Sciences Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  7/12/2016
Veterans Affairs Medical Center - Chicago Westside Hospital
mi
from
Chicago, IL
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 7/12/2016
Veterans Affairs Medical Center - Chicago Westside Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  7/12/2016
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 7/12/2016
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  7/12/2016
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 7/12/2016
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
Click here to add this to my saved trials
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  7/12/2016
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 7/12/2016
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  7/12/2016
Veterans Affairs Medical Center - Togus
mi
from
Togus, ME
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 7/12/2016
Veterans Affairs Medical Center - Togus
mi
from
Togus, ME
Click here to add this to my saved trials